Harrow Health Inc(HROWL)

25.16-0.12-0.47%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
Harrow Health Inc
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.imprimispharma.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Harrow Health, Inc.于2006年1月以Bywater资源公司之名组成于特拉华州，主要参与矿物质开发活动。2007年9月11日改名为Transdel制药公司,2018年12月13日更名为Harrow Health公司。该公司是一家以眼科为重点的制药公司，专门从事开发，生产和销售创新药物，提供独特的竞争优势并满足市场上未满足的需求。他们致力于履行公司的使命，以可承受的价格向医生和患者提供高质量的新药。
- 2024-01-09
  超过5%披露
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2024-01-03
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2023-11-24
  超过5%披露
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2023-11-14
  季度报告
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2023-11-14
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2023-11-03
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2023-09-29
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2023-08-18
  超过5%披露
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
- 2023-08-09
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2023-08-09
  季度报告
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2023-07-21
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2023-07-18
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2023-06-23
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2023-05-11
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2023-05-11
  季度报告
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]